

Clinical Trial Activity in Ontario Between 2015 – 2023

22

Clinical Trials

9 Completed
9 Active
4 Pending

100

Partners

4

Ontario Cities

750+

Patients

Billions

of Stem Cells!



BRAIN AND/OR NERVES

Phase I using a diabetes drug for brain repair in children with multiple sclerosis: Toronto (Active)

Phase I using engineered cell therapy for Parkinson's Disease: Active 2021

Phase II using stem cells for multiple sclerosis: Complete

Phase II using a diabetes drug for brain repair in children with cerebral palsy: Toronto (Active)

Phase III using a diabetes drug to stimulate brain repair for malignant brain tumours: Complete



GENETIC DISORDERS

Phase I using genetically modified stem cells for Fabry disease: Complete



BLOOD

Phase I using cell therapy to help patients recover from radiation/chemotherapies for the treatment of leukemia: Pending 2022–23



LIVER

Phase II–III using stem cells to induce tolerance in recipients of liver transplants: Ottawa and Toronto (Active)



JOINTS

Phase I–II using stem cells for knee osteoarthritis: Complete

Phase III using a cartilage tissue implant grown from patient's cells: Complete



BURNS

Phase I using stem cells developed from a patient's surgically removed burned tissue to improve wound healing: Active



MUSCLE

Phase I using a drug to restore muscle regeneration in children with muscular dystrophy: Pending 2022–23



PAIN

Phase I hydrogel-based drug delivery platform for treatment of post-surgical pain: Pending 2021



HEART

Phase I using stem cells to repair heart damage: Pending 2022–23

Phase II using genetically modified stem cells following a heart attack: Complete

Phase II using stem cells for advanced heart failure with left ventricular assist device: Complete

Phase II using cell therapy combined with coronary artery bypass grafting to treat heart failure: Complete



LUNG

Phase I using stem cells for bronchopulmonary dysplasia in pre-term infants: Active

Phase II using genetically modified stem cells for pulmonary arterial hypertension: London, Ottawa, Toronto and Hamilton (Active)



CRITICAL CARE

Phase I cell therapy for septic shock: Complete

Phase II cell therapy for septic shock: Active 2021

Phase I cell therapy for COVID-19 related acute respiratory distress syndrome: Ottawa, Toronto, Montreal (Active)

Five Disease Teams directly funded by OIRM with technologies now in **Phase I/II** trials.

Three Disease Teams directly funded by OIRM with technologies in **Phase I** trials in 1-2 years (2022-23).